These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 35481366)

  • 1. Direct oral anticoagulation in atrial fibrillation and heart valve surgery-a meta-analysis and systematic review.
    Gerfer S; Djordjevic I; Eghbalzadeh K; Mader N; Wahlers T; Kuhn E
    Ther Adv Cardiovasc Dis; 2022; 16():17539447221093963. PubMed ID: 35481366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Evidence-Based Approach to Anticoagulation Therapy Comparing Direct Oral Anticoagulants and Vitamin K Antagonists in Patients With Atrial Fibrillation and Bioprosthetic Valves: A Systematic Review, Meta-Analysis, and Network Meta-Analysis.
    Suppah M; Kamal A; Saadoun R; Baradeiya AMA; Abraham B; Alsidawi S; Sorajja D; Fortuin FD; Arsanjani R
    Am J Cardiol; 2023 Nov; 206():132-150. PubMed ID: 37703679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Benefit of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves.
    Russo V; Carbone A; Attena E; Rago A; Mazzone C; Proietti R; Parisi V; Scotti A; Nigro G; Golino P; D'Onofrio A
    Clin Ther; 2019 Dec; 41(12):2549-2557. PubMed ID: 31735436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and bioprosthetic valves: A meta-analysis.
    Yokoyama Y; Briasoulis A; Ueyama H; Mori M; Iwagami M; Misumida N; Takagi H; Kuno T
    J Thorac Cardiovasc Surg; 2023 Jun; 165(6):2052-2059.e4. PubMed ID: 34417050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uninterrupted anticoagulation during catheter ablation for atrial fibrillation: no difference in major bleeding and stroke between direct oral anticoagulants and vitamin K antagonists in an updated meta-analysis of randomised controlled trials.
    Brockmeyer M; Lin Y; Parco C; Karathanos A; Krieger T; Schulze V; Heinen Y; Bejinariu A; Müller P; Makimoto H; Kelm M; Wolff G
    Acta Cardiol; 2021 May; 76(3):288-295. PubMed ID: 32056498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DOAC versus VKA in patients with atrial fibrillation and bioprosthetic valves: a systematic review and meta-analysis.
    Guardia Martínez P; Avilés Toscano AL; Martínez Mayoral MA; Moltó Miralles J
    Rev Esp Cardiol (Engl Ed); 2023 Sep; 76(9):690-699. PubMed ID: 36804556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Direct Oral Anticoagulants for Stroke Prevention in Older Patients With Atrial Fibrillation: A Network Meta-Analysis of Randomized Controlled Trials.
    Lin DS; Lo HY; Huang KC; Lin TT; Lee JK
    J Am Heart Assoc; 2023 Dec; 12(23):e030380. PubMed ID: 38014696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation.
    Renda G; Zimarino M; Ricci F; Piccini JP; Ezekowitz MD; Patel MR; Cappato R; Giugliano RP; De Caterina R
    Am J Med; 2016 Oct; 129(10):1117-1123.e2. PubMed ID: 27262782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Nazha B; Pandya B; Cohen J; Zhang M; Lopes RD; Garcia DA; Sherwood MW; Spyropoulos AC
    Circulation; 2018 Oct; 138(14):1402-1411. PubMed ID: 29794081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular and renal outcomes in patients with atrial fibrillation and stage 4-5 chronic kidney disease receiving direct oral anticoagulants: a multicenter retrospective cohort study.
    Lin Y; Chao TF; Tsai ML; Tseng CJ; Wang TH; Chang CH; Lin YS; Yang NI; Chu PH; Hung MJ; Wu VC; Chen TH
    J Thromb Thrombolysis; 2024 Jan; 57(1):89-100. PubMed ID: 37605063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-Analysis Assessing Efficacy and Safety of Vitamin K Antagonists Versus Direct Oral Anticoagulants for Atrial Fibrillation After Transcatheter Aortic Valve Implantation.
    Selvaraj V; Khan MS; Mufarrih SH; Kazimuddin M; Waheed MA; Tripathi A; Bavishi C; Hyder ON; Aronow HD; Saad M; Abbott JD
    Am J Cardiol; 2023 Aug; 201():260-267. PubMed ID: 37393728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of thromboembolic events following atrial fibrillation catheter ablation and rate control strategies according to the kind of oral anticoagulation: A systematic review and meta-analysis.
    Toso E; Peyracchia M; Matta M; D'Ascenzo F; Gaita F; Kornej J; Hindricks G; Jared Bunch T; Saliba W
    Int J Cardiol; 2018 Nov; 270():172-179. PubMed ID: 29945808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of direct oral anticoagulants vs vitamin K antagonists in patients with atrial fibrillation and end-stage renal disease on hemodialysis: A systematic review and meta-analysis.
    Kyriakoulis I; Adamou A; Stamatiou I; Chlorogiannis DD; Kardoutsos I; Koukousaki D; Ntaios G
    Eur J Intern Med; 2024 Jan; 119():45-52. PubMed ID: 37648582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Periprocedural anticoagulation during left atrial ablation: interrupted and uninterrupted vitamin K-antagonists or uninterrupted novel anticoagulants.
    Brinkmeier-Theofanopoulou M; Tzamalis P; Wehrkamp-Richter S; Radzewitz A; Merkel M; Schymik G; van Mark G; Bramlage P; Schmitt C; Luik A
    BMC Cardiovasc Disord; 2018 Apr; 18(1):71. PubMed ID: 29703158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Harms of Direct Oral Anticoagulants in the Elderly for Stroke Prevention in Atrial Fibrillation and Secondary Prevention of Venous Thromboembolism: Systematic Review and Meta-Analysis.
    Sharma M; Cornelius VR; Patel JP; Davies JG; Molokhia M
    Circulation; 2015 Jul; 132(3):194-204. PubMed ID: 25995317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis.
    Pan KL; Singer DE; Ovbiagele B; Wu YL; Ahmed MA; Lee M
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28720644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is There a Role for Vitamin K Antagonist in the Management of Atrial Fibrillation in 2023?
    Burg MR; Ha ACT
    Curr Cardiol Rep; 2023 May; 25(5):391-399. PubMed ID: 36995540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis.
    Caldeira D; Rodrigues FB; Barra M; Santos AT; de Abreu D; Gonçalves N; Pinto FJ; Ferreira JJ; Costa J
    Heart; 2015 Aug; 101(15):1204-11. PubMed ID: 26037103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuous and minimally-interrupted direct oral anticoagulant are both safe compared with vitamin K antagonist for atrial fibrillation ablation: An updated meta-analysis.
    Ha FJ; Barra S; Brown AJ; Begley DA; Grace AA; Agarwal S
    Int J Cardiol; 2018 Jul; 262():51-56. PubMed ID: 29606512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.